Fundraising Fox

Phagenesis

3 known investors

Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing. The company serves patients with swallowing disorders caused by neurological conditions, supported by 25 years of clinical research and evidence.

Deep TechDigital HealthHealthtechMedical Devices

Investors · 3

Aphelion Capital
Innvotec Ltd.London · $317.5K – $635K
Northern Gritstone

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Phagenesis went on to found or lead other companies.

Oern R. StugeChairmanFounded Impulse Dynamics +1Daniel GreenCEOFounded Precision Microbubbles

In the news

Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent Close of $42M Series D Financing - Phagenesisphagenesis.com · Sep 2024Phagenesis: $42 Million To Develop Neurostimulation System To Treat Swallowing Dysfunctionpulse2.com · Mar 2024Phagenesis raises £33m for device treating effects of brain injuryuktech.news · Mar 2024Phagenesis Successfully Closes a $42M Series D Financing Round Led by EQT Life Sciences and Sectoral Asset Management - Phagenesisphagenesis.com · Mar 2024Report: Pharyngeal neurostim company Phagenesis raises $42Mmassdevice.com · Mar 2024Advising Phagenesis on its US$42 million Series D financing roundtaylorwessing.com · Feb 2024

Frequently asked questions

What does Phagenesis do?
Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing. The company serves patients with swallowing disorders caused by neurological conditions, supported by 25 years of clinical research and evidence.
Who are Phagenesis's investors?
Phagenesis's investors include Aphelion Capital, Innvotec Ltd., Northern Gritstone.